AcelRx Obtains Troubled Antibiotic Firm Tetraphase In Stock Swap

 
• By Joseph Haas

Deal Snapshot: Unable to make a go of selling novel antibiotic Xerava, Tetraphase’s product and commercial team will be absorbed into AcelRx in $14.4m deal.

Antibiotics. Medical Report with Composition of Medicaments - LIght Green Pills, Injections and Syringe. Blurred Background with Selective Focus.
The challenging market conditions for novel antibiotics finally proved too great for Tetraphase

More from Deals

More from Business